# Modulation of inflammasome components in patients with heart failure using oral nutritional supplements: investigating the molecular mechanisms beyond the clinical benefit

**Authors:** Aura D. Herrera-Martínez, Natalia Hermán-Sánchez, Miguel E. G-García, Concepción Muñoz-Jiménez, Jesús M. Pérez-Gómez, Antonio J. Montero-Hidalgo, José López-Aguilera, Rafael González-Manzanares, María Ángeles Gálvez-Moreno, María José Molina-Puerta, Raúl M. Luque

PMC · DOI: 10.1007/s00394-025-03878-5 · European Journal of Nutrition · 2026-02-03

## TL;DR

This study shows that adding high-protein supplements with EPA and DHA to a Mediterranean diet can reduce inflammation in heart failure patients by altering inflammasome pathways.

## Contribution

The study reveals novel molecular mechanisms by which specific nutritional supplements modulate inflammasome components in heart failure.

## Key findings

- Supplements reduced expression of inflammasome components like NLRP12, NLRP6, CASP5, TLR2, and TLR9.
- Cytokines and inflammation-related molecules such as CXCR1, CXCR2, and CCL2 were downregulated.
- Cell cycle regulators like CDKN2D decreased, suggesting effects on cellular senescence and DNA repair.

## Abstract

Inflammation is a key contributor to the pathogenesis and progression of heart failure (HF), correlating with increased morbidity and mortality. This study aimed to evaluate the molecular impact of a 24-week nutritional intervention on inflammasome-related components in HF patients, comparing a Mediterranean diet alone versus the same diet supplemented with hypercaloric, high-protein oral nutritional supplements (ONS) enriched with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In a cohort of 38 patients, expression levels of inflammasome markers were assessed via microfluidic quantitative polymerase chain reaction (PCR) in peripheral blood mononuclear cells at baseline and post-intervention.

Some components, especially cytokines and apoptosis regulation components are overexpressed in patients with sarcopenia (NLRP1, NLRC4, CASP1, CASP5, CTSL, IFI16, TLR8, PSXR7, CCR1, CHUCK, MAPK14, CDKN1B). We observed a significant downregulation of Nod-like receptors NLRP12 and NLRP6, along with decreased expression of inflammasome activation components CASP5, TLR2, and TLR9 in the intervention group (p < 0.05). Additionally, cytokines and inflammation-related molecules such as CXCR1, CXCR2, TGFB, CCL2, and NF-κB showed reduced expression, while the inhibitor CHUCK increased (p < 0.05). Cell cycle regulators also shifted, with decreased CDKN2D expression (p < 0.05), suggesting potential effects on cellular senescence and DNA repair pathways. Notably, these molecular changes were absent in patients adhering solely to the Mediterranean diet.

these findings suggest that supplementing a Mediterranean diet with hypercaloric, high-protein, EPA and DHA-enriched ONS induces molecular modifications in inflammasome pathways associated with cardiac remodeling. Therefore, targeted nutritional strategies may offer a promising adjunct to improve cardiac function and disease progression in HF patients.

The online version contains supplementary material available at 10.1007/s00394-025-03878-5.

## Linked entities

- **Genes:** NLRP1 (NLR family pyrin domain containing 1) [NCBI Gene 22861], NLRC4 (NLR family CARD domain containing 4) [NCBI Gene 58484], CASP1 (caspase 1) [NCBI Gene 834], CASP5 (caspase 5) [NCBI Gene 838], CTSL (cathepsin L) [NCBI Gene 1514], IFI16 (interferon gamma inducible protein 16) [NCBI Gene 3428], TLR8 (toll like receptor 8) [NCBI Gene 51311], CCR1 (C-C motif chemokine receptor 1) [NCBI Gene 1230], MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432], CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027], NLRP12 (NLR family pyrin domain containing 12) [NCBI Gene 91662], NLRP6 (NLR family pyrin domain containing 6) [NCBI Gene 171389], TLR2 (toll like receptor 2) [NCBI Gene 7097], TLR9 (toll like receptor 9) [NCBI Gene 54106], CXCR1 (C-X-C motif chemokine receptor 1) [NCBI Gene 3577], CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], CDKN2D (cyclin dependent kinase inhibitor 2D) [NCBI Gene 1032]
- **Chemicals:** eicosapentaenoic acid (PubChem CID 5282847), docosahexaenoic acid (PubChem CID 445580)
- **Diseases:** heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** CTSL (cathepsin L) [NCBI Gene 1514] {aka CATL, CTSL1, MEP}, NLRP1 (NLR family pyrin domain containing 1) [NCBI Gene 22861] {aka AIADK, CARD7, CIDED, CLR17.1, DEFCAP, DEFCAP-L/S}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, CUX1 (cut like homeobox 1) [NCBI Gene 1523] {aka CASP, CDP, CDP/Cut, CDP1, COY1, CUTL1}, CXCR1 (C-X-C motif chemokine receptor 1) [NCBI Gene 3577] {aka C-C, C-C-CKR-1, CD128, CD181, CDw128a, CKR-1}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, CASP5 (caspase 5) [NCBI Gene 838] {aka ICE(rel)III, ICEREL-III, ICH-3}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, AIM2 (absent in melanoma 2) [NCBI Gene 9447] {aka PYHIN4}, CHUK (component of inhibitor of nuclear factor kappa B kinase complex) [NCBI Gene 1147] {aka BPS2, IKBKA, IKK-1, IKK-alpha, IKK1, IKKA}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, CCR5 (C-C motif chemokine receptor 5) [NCBI Gene 1234] {aka CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, HPRT1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 3251] {aka HGPRT, HPRT}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, CDKN2D (cyclin dependent kinase inhibitor 2D) [NCBI Gene 1032] {aka INK4D, p19, p19-INK4D}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, NLRP7 (NLR family pyrin domain containing 7) [NCBI Gene 199713] {aka CLR19.4, HYDM, NALP7, NOD12, OZEMA25, PAN7}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, TLR8 (toll like receptor 8) [NCBI Gene 51311] {aka CD288, IMD98, TLR-8, hTLR8}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, CCR1 (C-C motif chemokine receptor 1) [NCBI Gene 1230] {aka CD191, CKR-1, CKR1, CMKBR1, HM145, MIP1aR}, CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027] {aka CDKN4, KIP1, MEN1B, MEN4, P27KIP1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TRL-AAG2-3 (tRNA-Leu (anticodon AAG) 2-3) [NCBI Gene 7207] {aka TRL-AAG2-1, TRL1, TRNAL1, TRNP1}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, NLRP6 (NLR family pyrin domain containing 6) [NCBI Gene 171389] {aka AVR, CLR11.4, NALP6, NAVR, NAVR/AVR, PAN3}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, NLRP12 (NLR family pyrin domain containing 12) [NCBI Gene 91662] {aka CLR19.3, FCAS2, NALP12, PAN6, PYPAF7, RNO}, IFI16 (interferon gamma inducible protein 16) [NCBI Gene 3428] {aka IFNGIP1, PYHIN2}, NLRC4 (NLR family CARD domain containing 4) [NCBI Gene 58484] {aka AIFEC, CARD12, CLAN, CLAN1, CLANA, CLANB}, GSDMD (gasdermin D) [NCBI Gene 79792] {aka DF5L, DFNA5L, FKSG10, GSDMDC1}
- **Diseases:** cardiac hypertrophy (MESH:D006332), acute coronary syndrome (MESH:D054058), obesity (MESH:D009765), cardiac remodeling (MESH:D020257), Sarcopenia (MESH:D055948), dilated cardiomyopathy (MESH:D002311), cancer (MESH:D009369), fibrosis (MESH:D005355), melanoma (MESH:D008545), muscle atrophy (MESH:D009133), autoinflammatory (MESH:D056660), myocardial remodeling (MESH:D064752), Atherosclerosis (MESH:D050197), chronic (MESH:D002908), muscle (MESH:D019042), cardiometabolic disorders (MESH:D024821), peripheric arterial disease (MESH:D058729), HF (MESH:D006333), left ventricular dilation and dysfunction (MESH:D018487), Malnutrition (MESH:D044342), heart remodeling (MESH:D066253), cardiovascular disease (MESH:D002318), hypertrophy (MESH:D006984), left ventricular hypertrophy (MESH:D017379), myocardial ischemia (MESH:D017202), Inflammation (MESH:D007249), weight gain (MESH:D015430), cardiac dysfunction (MESH:D006331)
- **Chemicals:** sugars (MESH:D000073893), NT-proBNP (-), thiamine (MESH:D013831), EPA (MESH:D015118), calcifediol (MESH:D002112), n-3 PUFAs (MESH:D015525), isoproterenol (MESH:D007545), DHA (MESH:D004281), EDTA (MESH:D004492), PUFAs (MESH:D005231), D-ribose (MESH:D012266), carbohydrates (MESH:D002241), L-arginine (MESH:D001120), triglycerides (MESH:D014280), 25-hydroxyvitamin D (MESH:C104450), HMB (MESH:C004961)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12868064/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12868064/full.md

---
Source: https://tomesphere.com/paper/PMC12868064